$ENTA
ENANTA PHARMACEUTICALS INC

2024 Q1 Form 10-Q Financial Statement

#000095017024012796 Filed on February 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4
Revenue $17.05M $18.00M
YoY Change -4.16% -23.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.24M $16.52M
YoY Change 3.32% 30.1%
% of Gross Profit
Research & Development $35.59M $36.37M
YoY Change -18.14% -11.08%
% of Gross Profit
Depreciation & Amortization $621.0K $642.0K
YoY Change 15.0% 25.64%
% of Gross Profit
Operating Expenses $35.59M $36.37M
YoY Change -18.14% -11.08%
Operating Profit -$32.77M -$34.89M
YoY Change -16.95% 16.24%
Interest Expense $2.563M $3.441M
YoY Change 39.52% 246.53%
% of Operating Profit
Other Income/Expense, Net $1.246M $857.0K
YoY Change -32.17% -13.7%
Pretax Income -$31.52M -$34.03M
YoY Change -16.2% 17.26%
Income Tax -$363.0K -$622.0K
% Of Pretax Income
Net Earnings -$31.16M -$33.41M
YoY Change -17.26% 15.25%
Net Earnings / Revenue -182.7% -185.56%
Basic Earnings Per Share -$1.47 -$1.58
Diluted Earnings Per Share -$1.47 -$1.58
COMMON SHARES
Basic Shares Outstanding 21.16M 21.06M
Diluted Shares Outstanding 21.17M 21.09M

Balance Sheet

Concept 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $300.3M $337.2M
YoY Change 42.95% 57.2%
Cash & Equivalents $63.54M $39.93M
Short-Term Investments $236.8M $297.2M
Other Short-Term Assets $10.93M $13.25M
YoY Change -24.52% -26.2%
Inventory
Prepaid Expenses
Receivables $7.756M $8.173M
Other Receivables $32.03M $31.73M
Total Short-Term Assets $351.0M $390.3M
YoY Change 29.47% 37.57%
LONG-TERM ASSETS
Property, Plant & Equipment $15.48M $12.12M
YoY Change 40.08% 39.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $187.0K $765.0K
YoY Change -73.13% 9.13%
Total Long-Term Assets $62.53M $38.20M
YoY Change 13.05% -40.16%
TOTAL ASSETS
Total Short-Term Assets $351.0M $390.3M
Total Long-Term Assets $62.53M $38.20M
Total Assets $413.6M $428.5M
YoY Change 26.69% 23.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.726M $9.326M
YoY Change -42.81% 114.29%
Accrued Expenses $10.63M $11.60M
YoY Change -31.34% -23.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.61M $62.41M
YoY Change 69.77% 171.32%
LONG-TERM LIABILITIES
Long-Term Debt $1.423M $1.423M
YoY Change 0.0% 0.0%
Other Long-Term Liabilities $224.0K $649.0K
YoY Change -45.1% 56.76%
Total Long-Term Liabilities $224.0K $649.0K
YoY Change -45.1% 56.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.61M $62.41M
Total Long-Term Liabilities $224.0K $649.0K
Total Liabilities $247.4M $236.6M
YoY Change 333.58% 406.7%
SHAREHOLDERS EQUITY
Retained Earnings -$271.6M -$240.4M
YoY Change 94.22% 135.31%
Common Stock $438.3M $432.8M
YoY Change 6.65% 6.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $166.1M $191.9M
YoY Change
Total Liabilities & Shareholders Equity $413.6M $428.5M
YoY Change 26.69% 23.3%

Cashflow Statement

Concept 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$31.16M -$33.41M
YoY Change -17.26% 15.25%
Depreciation, Depletion And Amortization $621.0K $642.0K
YoY Change 15.0% 25.64%
Cash From Operating Activities -$28.60M -$24.99M
YoY Change 107.51% -29.89%
INVESTING ACTIVITIES
Capital Expenditures $1.668M $787.0K
YoY Change -30.0% -75.06%
Acquisitions
YoY Change
Other Investing Activities $60.29M -$12.33M
YoY Change 22.67% -133.57%
Cash From Investing Activities $58.62M -$13.12M
YoY Change 25.36% -139.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -6.414M -7.350M
YoY Change 216.43% -2541.86%
NET CHANGE
Cash From Operating Activities -28.60M -24.99M
Cash From Investing Activities 58.62M -13.12M
Cash From Financing Activities -6.414M -7.350M
Net Change In Cash 23.61M -45.46M
YoY Change -23.73% 2466.63%
FREE CASH FLOW
Cash From Operating Activities -$28.60M -$24.99M
Capital Expenditures $1.668M $787.0K
Free Cash Flow -$30.27M -$25.78M
YoY Change 87.24% -33.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001177648
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
001-35839
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
ENANTA PHARMACEUTICALS, INC
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3205099
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
500 Arsenal Street
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2023Q4 dei City Area Code
CityAreaCode
617
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
607-0800
CY2023Q4 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2023Q4 dei Trading Symbol
TradingSymbol
ENTA
CY2023Q4 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21155983
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39933000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85388000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
297218000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
284522000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8173000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8614000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13245000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13263000
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
31734000
CY2023Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
31004000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
390303000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
422791000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12119000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11919000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21344000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22794000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3968000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3968000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
765000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
803000
CY2023Q4 us-gaap Assets
Assets
428499000
CY2023Q3 us-gaap Assets
Assets
462275000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9326000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4097000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11603000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18339000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
36512000
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
35076000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4966000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5275000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62407000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
62787000
CY2023Q4 enta Accrued Royalties Noncurrent
AccruedRoyaltiesNoncurrent
151612000
CY2023Q3 enta Accrued Royalties Noncurrent
AccruedRoyaltiesNoncurrent
159429000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20524000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21238000
CY2023Q4 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1423000
CY2023Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1423000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
649000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
663000
CY2023Q4 us-gaap Liabilities
Liabilities
236615000
CY2023Q3 us-gaap Liabilities
Liabilities
245540000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21156000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21156000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21059000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21059000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
212000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
211000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
432608000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
424693000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-534000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1174000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240402000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206995000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
191884000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
216735000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
428499000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462275000
CY2023Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18003000
CY2022Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23585000
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36371000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40902000
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16518000
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12696000
CY2023Q4 us-gaap Costs And Expenses
CostsAndExpenses
52889000
CY2022Q4 us-gaap Costs And Expenses
CostsAndExpenses
53598000
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-34886000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-30013000
CY2023Q4 us-gaap Interest Expense
InterestExpense
3441000
CY2022Q4 us-gaap Interest Expense
InterestExpense
0
CY2023Q4 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4298000
CY2022Q4 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
993000
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
857000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
993000
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34029000
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29020000
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-622000
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-33407000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-28986000
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21088000
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21088000
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20816000
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20816000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-33407000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-28986000
CY2023Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
640000
CY2022Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1049000
CY2023Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
640000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1049000
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32767000
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27937000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
216735000
CY2023Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-183000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8099000
CY2023Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
640000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-33407000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
191884000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
321334000
CY2022Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1126000
CY2022Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-825000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7139000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1049000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-28986000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
300837000
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-33407000
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-28986000
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
8099000
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
7139000
CY2023Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
642000
CY2022Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
511000
CY2023Q4 enta Non Cash Interest Expense Associated With The Sale Of Future Royalties
NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties
299000
CY2022Q4 enta Non Cash Interest Expense Associated With The Sale Of Future Royalties
NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties
0
CY2023Q4 enta Payments For Royalty Liabilities
PaymentsForRoyaltyLiabilities
-487000
CY2022Q4 enta Payments For Royalty Liabilities
PaymentsForRoyaltyLiabilities
0
CY2023Q4 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-274000
CY2022Q4 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
339000
CY2023Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-441000
CY2022Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2267000
CY2023Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000
CY2022Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4501000
CY2023Q4 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
730000
CY2022Q4 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-15000
CY2023Q4 enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1450000
CY2022Q4 enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-834000
CY2023Q4 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-38000
CY2022Q4 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5000
CY2023Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5174000
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-686000
CY2023Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6736000
CY2022Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6599000
CY2023Q4 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1023000
CY2022Q4 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-717000
CY2023Q4 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-14000
CY2022Q4 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-40000
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24988000
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35641000
CY2023Q4 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
146845000
CY2022Q4 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
67375000
CY2023Q4 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
134515000
CY2022Q4 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
104100000
CY2023Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
787000
CY2022Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3156000
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13117000
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33569000
CY2023Q4 enta Payments On Royalty Sale Liability Net Of Imputed Interest
PaymentsOnRoyaltySaleLiabilityNetOfImputedInterest
7167000
CY2022Q4 enta Payments On Royalty Sale Liability Net Of Imputed Interest
PaymentsOnRoyaltySaleLiabilityNetOfImputedInterest
0
CY2023Q4 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
183000
CY2022Q4 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
825000
CY2023Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1126000
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7350000
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
301000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45455000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1771000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
89356000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47962000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43901000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46191000
CY2023Q4 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
479000
CY2022Q4 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1079000
CY2023Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
799000
CY2023Q4 us-gaap Interest Paid Net
InterestPaidNet
3143000
CY2022Q4 us-gaap Interest Paid Net
InterestPaidNet
0
CY2023Q4 us-gaap Year Founded
YearFounded
1995
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-33407000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-133816000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240402000
CY2023Q4 enta Cash Cash Equivalents Short Term And Long Term Marketable Securities
CashCashEquivalentsShortTermAndLongTermMarketableSecurities
337151000
CY2023Q4 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, management’s judgments with respect to its revenue arrangements; liability related to the sale of future royalties; valuation of stock-based awards and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span></p>
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1092000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
336123000
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1423000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
369634000
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1423000
CY2023Q4 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2022Q4 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
297368000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
207000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
357000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
297218000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
285312000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
802000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
284522000
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.99
CY2023Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
244000
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
38.99
CY2023Q4 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
1099000
CY2023Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
3083000
CY2023Q4 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3707000
CY2023Q3 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
6120000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4310000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7037000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2487000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2099000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11603000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18339000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4365000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.68
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5213000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.17
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
459000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5213000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
44.17
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
459000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3028000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
53.37
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M6D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8099000
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7139000
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8099000
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7139000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
60806
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-622000
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-012796-index-headers.html Edgar Link pending
0000950170-24-012796-index.html Edgar Link pending
0000950170-24-012796.txt Edgar Link pending
0000950170-24-012796-xbrl.zip Edgar Link pending
enta-20231231.htm Edgar Link pending
enta-20231231.xsd Edgar Link pending
enta-ex31_1.htm Edgar Link pending
enta-ex31_2.htm Edgar Link pending
enta-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img216065237_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
enta-20231231_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending